Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3616 + TQB2450 in Resistant Digestive System Tumors
NCT05139082Phase 2Unknown
- Sponsor
- Peking University
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of culmerciclib, benmelstobart in digestive system neoplasm, sponsored by Peking University. Status: unknown.
02
Drugs
culmerciclibbenmelstobart
03
Conditions
digestive system neoplasm
Beyond the preview
Go deeper on NCT05139082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139082.